Gland Pharma · NSE: GLAND · BSE: 543245
Q4 FY26 results · Jan–Mar 2026
Gland Pharma reported revenue from operations of ₹1,742.79 crore (up 22.3% from Q4 FY25) and net profit of ₹366.68 crore (up 96.6% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,742.79 | 1,424.91 | +22.3% | 1,695.36 | +2.8% |
| Other income | 111.47 | 44.03 | +153.2% | 63.17 | +76.4% |
| Total income | 1,854.26 | 1,468.94 | +26.2% | 1,758.54 | +5.4% |
| Profit before tax | 505.80 | 288.33 | +75.4% | 362.13 | +39.7% |
| Net profit for the period | 366.68 | 186.54 | +96.6% | 261.48 | +40.2% |
| EPS, basic (₹) | 22.26 | 11.32 | +96.6% | 15.87 | +40.3% |
| Net margin (%) | 21.0 | 13.1 | 15.4 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,261.59 | 1,030.35 | +22.4% | 1,177.51 | +7.1% |
| Other income | 106.36 | 43.72 | +143.3% | 60.21 | +76.7% |
| Total income | 1,367.95 | 1,074.07 | +27.4% | 1,237.72 | +10.5% |
| Profit before tax | 564.80 | 391.32 | +44.3% | 412.46 | +36.9% |
| Net profit for the period | 420.45 | 290.00 | +45.0% | 307.85 | +36.6% |
| EPS, basic (₹) | 25.52 | 17.60 | +45.0% | 18.68 | +36.6% |
| Net margin (%) | 33.3 | 28.1 | 26.1 |
Consolidated
- Filed with BSE
- 15 May 2026, 21:09 IST
- Board meeting
- 15 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 15 May 2026, 21:09 IST
- Board meeting
- 15 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE